Amycretin is a copy of the gut hormone GLP-1. Pramlintide is a copy of amylin.
GLP-1 is what your gut releases after a meal to tell your brain you have eaten.
The difference is reach: Pramlintide acts on 1 receptor and Amycretin acts on 2 receptors. More receptors has generally meant more effect, and more side effects.
| Comparison | Amycretin | Pramlintide Symlin |
|---|---|---|
| How it works | How it works Amycretin is a single molecule carrying two different fullness signals, GLP-1 and amylin. CagriSema achieves something similar by combining two drugs; this does it with one. | How it works Pramlintide copies amylin, and it was the first drug in this family, approved back in 2005 for use alongside insulin rather than for weight loss. |
| What it is | An experimental two-in-one weight-loss compound, as a pill or a shot. | An approved mealtime shot used with insulin to blunt blood-sugar spikes and hunger. |
| Status | In trialsInvestigational | FDA approvedFDA-approved |
| Typical dose | 0.3–60 mg per week | 0.015–0.12 mg per dose |
| How often | Weekly/daily | With meals |
| Stays active | Not established | ~48 minutes |
| Dose comes from | Clinical trial protocol | FDA drug label |
| Cycled? | Not cycled in the trials Clinical trial protocol | Not cycled FDA drug label |
| What it does | ||
| Drug class | GLP-1 + amylin (one molecule) | Amylin analog |
| Used for | An experimental compound that combines two appetite-lowering effects in one, with strong early weight-loss numbers. It comes as a pill and a shot in trials. | An approved mealtime shot used with insulin in diabetes. It blunts the blood-sugar spike after eating and reduces hunger. |
| Receptors hit | GLP-1, amylin | amylin |
| Numbers | ||
| Full dose line | 0.3 up to 60 mg per week (start low, increase slowly) | 0.015 up to 0.12 mg per dose (start low, increase slowly) |
| Why that cycle | Given continuously for the whole study period: 36 weeks injected, 12 weeks oral. The dose is stepped up at the start, which is a ramp rather than a cycle, and no trial in this class built in a planned break. | Taken continuously for as long as it is working. Neither the label nor clinical practice describes an on/off schedule. |
| Weight / effect | Not measured in a trial | Not measured in a trial |
| Chain length | 68 residues | 37 residues |
| Common vial | 10 mg | 5 mg |
| Before you start | ||
| Route | By mouth or under the skin | Under the skin (subcutaneous) |
| Do not use if | No formal contraindications established Pregnancy | Not being able to feel low blood sugar coming on (hypoglycemia unawareness) Severe stomach-emptying problems (gastroparesis) Pregnancy |
What separates them
Proof behind the dose. Pramlintide has a dose taken straight off an FDA drug label. Amycretin has a dose from a clinical trial protocol.
What doesn't differ: Neither has a measured effect size from a published trial, so there is no number to rank them on.
What people actually report
Amycretin
- Stomach side effects are expected.
- It is trial-only and not available.
- Vomiting badly enough that you cannot keep fluids down
- Severe stomach pain that spreads to your back
Pramlintide
- It can cause low blood sugar when used with insulin, plus nausea.
- Signs of severe low blood sugar such as confusion, shaking, sweating, or fainting, which is the boxed warning on this drug
- Severe or persistent vomiting
Side effects are what users and trials report most often, not a complete list. Anything sudden, spreading, or breathing-related is an emergency regardless of which compound caused it.
People also compare
This comparison does not cover cost, long-term safety, or how you personally will respond. Effect figures come from separate trials in different populations and are not always directly comparable to each other. Nothing here is medical advice or a recommendation to use any of these. Talk to a clinician about your own situation.